-
Product Insights
New![]()
Net Present Value Model: Ultragenyx Pharmaceutical Inc’s UX-701
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – UX-701 in Wilson Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.UX-701 in Wilson Disease Drug Details:UX-701 (DTX-701) is under development for the treatment of Wilson disease....
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Giredestrant
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: BGBA-445 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XBH-25 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.XBH-25 in Solid TumorDrug Details:XHB-25 Â under development for the treatment of advanced or refractory solid tumor...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CBP-1019 in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1019 in Breast Cancer Drug Details: CBP-1019 is under development for the treatment of lung...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Xeruborbactam in Acinetobacter Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Xeruborbactam in Acinetobacter Infections Drug Details: Xeruborbactam is under development for the treatment of carbapenem-resistant...
-
Product Insights
![]()
Salboy Ltd – UX Manchester Mixed-Use Community – Manchester
Equip yourself with the essential tools needed to make informed and profitable decisions with our Salboy Ltd - UX Manchester Mixed-Use Community - Manchester report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Company Profile
![]()
OneTrust LLC – Company Profile
OneTrust LLC (OneTrust) is a provider of privacy management software platforms. The company's platform supports organizations to adhere to compliance with the data privacy, governance, and security regulations across sectors and jurisdictions. Its offerings include privacy program management, marketing, and privacy UX, third party risk management, governance, risk, compliance, audit, consent and preference management, regulations acts, and frameworks. OneTrust also provides professional services, training, certifications, partnerships, and integrations. It has operations in London, Georgia, Bengaluru, Melbourne, San Francisco, New York,...
Add to Basket -
Company Profile
![]()
Prevas AB – Company Profile
Prevas AB (Prevas) is a provider of industrial IT products and solutions. The company offers automation and robotic solutions, embedded systems and intelligent sensors, enterprise asset management, IoT solutions, product and platform-based solutions, product life cycle management, and smart services. It also provides medical technology products, manufacturing execution systems, industrial IT products, field services, digitalization, software design, support and application operations, UX & UI, and mobility systems. The company serves life science, products and units, engineering manufacturing, energy, defense, telecom,...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.